<DOC>
	<DOCNO>NCT01539512</DOCNO>
	<brief_summary>This Phase 3 , randomize , double-blind , placebo-controlled study evaluate effect idelalisib combination rituximab onset , magnitude , duration tumor control participants previously treat chronic lymphocytic leukemia ( CLL ) . Eligible patient randomize 1:1 ratio 1 2 treatment arm receive either idelalisib plus rituximab placebo plus rituximab . Participants tolerate primary study therapy experience definitive CLL progression eligible receive active idelalisib therapy extension study , GS-US-312-0117 .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Study Idelalisib Combination With Rituximab Previously Treated Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion : Adult subject previously treat recurrent CLL measurable lymphadenopathy Require therapy CLL Have experience CLL progression &lt; 24 month since completion last prior therapy Currently sufficiently fit receive cytotoxic therapy chemotherapyinduced bone marrow damage comorbidities .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>CLL</keyword>
	<keyword>CAL-101</keyword>
	<keyword>GS 1101</keyword>
	<keyword>PI3K</keyword>
	<keyword>GS-US-312-0117</keyword>
	<keyword>idelalisib</keyword>
</DOC>